Li, J., Sun, W., Zhu, X., Mei, Y., Li, W., & Li, J
Why Perfect B Is Evaluating AOD 9604: Our Clinical Perspective We began our internal evaluation of AOD 9604 in response to a consistent pattern we were seeing with patients in our South Florida practice: people who had experienced meaningful fat loss on GLP-1 medications, then plateaued or discontinued due to side effects, and were looking for a next option
By activating SIRT1 and preserving NAD, 5-Amino-1MQ supports fat oxidation while protecting muscle tissue , even during caloric restriction
While many peptides are considered safe, side effects can occur, and its important to discuss any unusual symptoms with your healthcare provider
It may be relevant when remodeling occurs under metabolic strain, including GLP-1 use, caloric deficit, chronic fatigue, or age-related NAD+ decline
Evidence for non-injectable routes is limited at best